Modality
Degrader
MOA
Anti-Tau
Target
VEGF
Pathway
Wnt
ADHDSCLC
Development Pipeline
Preclinical
~Jul 2011
→ ~Oct 2012
Phase 1
~Jan 2013
→ ~Apr 2014
Phase 2
~Jul 2014
→ ~Oct 2015
Phase 3
~Jan 2016
→ ~Apr 2017
NDA/BLA
Jul 2017
→ May 2026
NDA/BLACurrent
NCT05024244
120 pts·ADHD
2025-02→2025-10·Completed
NCT07256886
2,744 pts·ADHD
2017-07→2026-05·Not yet recruiting
2,864 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2025-10-076mo agoPh3 Readout· ADHD
2026-05-021mo awayPh3 Readout· ADHD
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
NDA/BLA
Not yet…
NDA/BLA
Complet…
Catalysts
Ph3 Readout
2025-10-07 · 6mo ago
ADHD
Ph3 Readout
2026-05-02 · 1mo away
ADHD
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05024244 | NDA/BLA | ADHD | Completed | 120 | ACR20 |
| NCT07256886 | NDA/BLA | ADHD | Not yet recr... | 2744 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-7558 | Roche | Phase 1 | SGLT2 | |
| NVS-5439 | Novartis | Preclinical | BET | |
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF | |
| Bemazumab | Regeneron | Phase 1 | VEGF | |
| REG-2172 | Regeneron | Phase 1/2 | PCSK9 | |
| BGN-3305 | BeiGene | Phase 2 | BCMA | |
| Pemicapivasertib | Legend Biotech | Phase 3 | VEGF |